

Supplementary Online Content

Lynch DR, Perlman SL, Meier T. A phase 3, double-blind, placebo-controlled trial of idebenone in Friedreich ataxia. *Arch Neurol*. 2010;67(8):941-947.

eTable. Adverse events in study subjects.

This supplementary material has been provided by the authors to give readers additional information about their work.

eTable. Adverse Events in Study Subjects

AE preferred term	Placebo (N=24)		Idebenone 450/900 mg/d (N=22)		Idebenone 1350/2250 mg/d (N=24)		Total (N=70)	
	N	%	N	%	N	%	N	%
Headache	9	37.5	6	27.3	12	50.0	27	38.6
Upper respiratory tract infection	9	37.5	3	13.6	4	16.7	16	22.9
Fatigue	3	12.5	3	13.6	4	16.7	10	14.3
Nausea	3	12.5	2	9.1	5	20.8	10	14.3
Pyrexia	3	12.5	4	18.2	3	12.5	10	14.3
Abdominal pain upper	1	4.2	2	9.1	6	25	9	12.9
Diarrhea	3	12.5	4	18.2	2	8.3	9	12.9
Dizziness	3	12.5	2	9.1	4	16.7	9	12.9
Muscle spasms	2	8.3	4	18.2	3	12.5	9	12.9
Pharyngolaryngeal pain	4	16.7	1	4.5	4	16.7	9	12.9
Limb injury	3	12.5	2	9.1	3	12.5	8	11.4
Abdominal pain	3	12.5	0	0	4	16.7	7	10
Fall	1	4.2	1	4.5	5	20.8	7	10
Pain in extremity	1	4.2	3	13.6	3	12.5	7	10
Vomiting	3	12.5	1	4.5	2	8.3	6	8.6
Back pain	1	4.2	2	9.1	2	8.3	5	7.1
Nasopharyngitis	0	0	2	9.1	3	12.5	5	7.1
Cough	1	4.2	0	0	3	12.5	4	5.7
Dyspepsia	1	4.2	0	0	3	12.5	4	5.7
Ear infection	2	8.3	2	9.1	0	0	4	5.7
Epistaxis	1	4.2	1	4.5	2	8.3	4	5.7
Influenza	1	4.2	0	0	3	12.5	4	5.7
Joint sprain	0	0	2	9.1	2	8.3	4	5.7
Rhinitis	2	8.3	1	4.5	1	4.2	4	5.7
Skin laceration	2	8.3	1	4.5	1	4.2	4	5.7

Number and percentage of patients experiencing adverse events. All AEs that occurred in more than 5% of the total study population are listed.